https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9-en.html Drugnews｜藥時事 en 2026-08-26T00:00:00.000Z Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses? https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html Drugnews｜藥時事 zh-tw 2026-08-26T00:00:00.000Z 默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？ https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en.html Drugnews｜藥時事 en 2026-08-24T18:10:00.000Z The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD? https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology.html Drugnews｜藥時事 zh-tw 2026-08-24T18:10:00.000Z 主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？